Literature DB >> 1985202

Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

P L Earl1, S Koenig, B Moss.   

Abstract

The effects of C-terminal and internal deletions on the synthesis, transport, biological properties, and antigenicity of the human immunodeficiency virus type 1 envelope protein were determined. A family of recombinant vaccinia viruses that express N-terminal overlapping env proteins of 204, 287, 393, 502 (full-length gp120), 635, 747, and 851 (full-length gp160) amino acids was constructed. All of the proteins were detected in intra- and extracellular forms which differed in the extent of glycosylation. The 747- and 851-amino-acid proteins were cleaved, were expressed on the surface of infected cells, and bound CD4. The 635-amino-acid env protein was cleaved inefficiently, and both the precursor and product were secreted, indicating absence of the transmembrane sequence. The 635- as well as the 502-amino-acid protein, which was also largely secreted, could still bind CD4. Unexpectedly, the 393-amino-acid protein was anchored in the plasma membrane, but neither it nor smaller proteins bound to soluble CD4. When amino acids at the gp120-gp41 junction were deleted, proteolytic cleavage of gp160 did not occur. Nevertheless, gp160 was inserted into the plasma membrane and bound soluble CD4. The predominant conserved B-cell epitopes were mapped to gp41 and the C terminus of gp120, whereas cytotoxic T-cell epitopes were distributed throughout the length of the glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985202      PMCID: PMC240486     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

2.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

Authors:  S Koenig; P Earl; D Powell; G Pantaleo; S Merli; B Moss; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.

Authors:  T Mizukami; T R Fuerst; E A Berger; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.

Authors:  D Dowbenko; G Nakamura; C Fennie; C Shimasaki; L Riddle; R Harris; T Gregory; L Lasky
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Improved antigenicity of the HIV env protein by cleavage site removal.

Authors:  M P Kieny; R Lathe; Y Rivière; K Dott; D Schmitt; M Girard; L Montagnier; J Lecocq
Journal:  Protein Eng       Date:  1988-09

7.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.

Authors:  A Cordonnier; L Montagnier; M Emerman
Journal:  Nature       Date:  1989-08-17       Impact factor: 49.962

8.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

9.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

View more
  114 in total

1.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Authors:  R J Center; P L Earl; J Lebowitz; P Schuck; B Moss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Authors:  S Lee; K Peden; D S Dimitrov; C C Broder; J Manischewitz; G Denisova; J M Gershoni; H Golding
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Activation of fusion by the SER virus F protein: a low-pH-dependent paramyxovirus entry process.

Authors:  Shaguna Seth; Annelet Vincent; R W Compans
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  HIV-1 Envelope Glycoprotein Trafficking through the Endosomal Recycling Compartment Is Required for Particle Incorporation.

Authors:  Junghwa Kirschman; Mingli Qi; Lingmei Ding; Jason Hammonds; Krista Dienger-Stambaugh; Jaang-Jiun Wang; Lynne A Lapierre; James R Goldenring; Paul Spearman
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

9.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells.

Authors:  M Heinkelein; S Sopper; C Jassoy
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.